Type I interferon receptor
Assets acting on this target.
- Class
- Interferon
The type I interferon receptor is a two-part (heterodimeric) protein complex, made of IFNAR1 and IFNAR2 subunits, found on the surface of nearly all cells. It is the docking site for type I interferons, a family of signaling proteins including interferon-alpha and interferon-beta that form a core part of the innate immune system's antiviral defenses. When these interferons bind, the receptor triggers a signaling cascade that switches on hundreds of genes, producing an antiviral state and shaping how immune cells behave. Because this pathway can be therapeutically useful in opposite directions, medicines targeting it fall into two groups: interferon-beta biologics that activate the receptor to reinforce immune regulation, used in autoimmune diseases of the nervous system, and monoclonal antibodies that block the receptor to quiet down chronically overactive interferon signaling, relevant in autoimmune conditions marked by excessive interferon activity such as lupus. This dual use reflects the receptor's two faces: controlled signaling helps regulate immunity, while persistent, excessive signaling can drive tissue-damaging autoimmune disease. Modulating this receptor, whether by supplementing or by blocking its activity, therefore has relevance across viral, neurological, and autoimmune disease contexts.
By indication
Related mechanisms
Type I interferon receptor drugs compared
8 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Interferon alfa-2b (Intron A)Intron A | Merck & Co. | biologic (interferon) | Approved | Approved in Chronic Hepatitis B; Approved in Follicular Lymphoma; Approved in Melanoma |
| Interferon beta-1b | Bayer | biologic (interferon) | Approved | Approved in Multiple Sclerosis |
| peginterferon alfa-2a (Pegasys)Pegasys | pharmaand, Roche | Not recorded | Approved | Approved in Chronic Hepatitis B |
| peginterferon beta-1aPlegridy | Biogen | biologic | Approved | Approved in Multiple Sclerosis |
| Rebif (interferon beta 1a) | EMD Serono, Merck KGaA | biologic (interferon) | Approved | Approved in Multiple Sclerosis |
| Ropeginterferon alfa-2b (Besremi)Besremi | AOP Orphan Pharmaceuticals GmbH, PharmaEssentia Corporation | recombinant protein (pegylated interferon alfa-2b) | Approved | Approved in Essential Thrombocythemia; Approved in Polycythemia Vera; Phase 3 in Myelofibrosis |
| Human Serum Albumin/interferon alpha2b fusion protein | Tianjin SinoBiotech | biologic (registry-typed, subtype undisclosed) | Phase 1/2 | Phase 1/2 in Chronic Hepatitis B |
| Interferon-beta1 | Biogen | biologic (registry-typed, subtype undisclosed) | Stage not recorded | Not recorded |